Vivus Completes Enrollment in Phase II Study of Avanafil for ED

Vivus has completed patient enrollment in its Phase II clinical study of its investigational drug avanafil.

Avanafil is a highly selective, orally administered phosphodiesterase Type 5 inhibitor being developed to treat erectile dysfunction (ED).

This multicenter, double-blind, randomized, placebo-controlled, parallel-design clinical study enrolled 298 patients. The purpose of this study is to evaluate the safety and efficacy of a number of different doses of avanafil with the goal of selecting the appropriate doses for Phase III clinical trials.

Previous studies with avanafil have demonstrated a rapid onset of action and a half-life of 60 to 90 minutes. The company intends to announce results upon completion of the trial expected to be later this year.